Business
INmune Bio, Inc. Reports Third Quarter 2019 Financial Results and Provides Shareholder Update
LA JOLLA, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness
About this update from Inmune Bio Inc.
[{"type":"text","content":"LA JOLLA, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, today reported its financial results for the third quarter ended September 30, 2019 and is providing a business update.\n Q3 2019 and Recent Highlights: Launched NeuLiv™ program for the treatment of NASHPresented data related to lead compound XPro1595 at the Society for Neuroscience's annual meetingAnnounced a potential link between obesity and Alzheimer's Disease at the Society for Neuroscience 49th annual meeting: Dr. Malú Tansey’s new data was highlighted at the corresponding press conferenceAnnounced USPTO Allowance of Key Patent Covering the Company’s DN-TNF Platform Technology for Treating CancerPresented XPro1595 for Treating Neuroinflammation in Alzheimer's Disease at 2019 Alzheimer's Association International Conference (AAIC) Satellite SymposiumInvited to present at industry meetings in the US and EU including Targeting Innate Immunity Congress, Inflammasome Therapeutics Summit and Markets&Markets Next Gen Immuno-Oncology Congress “During the quarter we advanced our existing programs and expanded our pipeline of therapies reprograming the innate immune system to fight disease,” stated RJ Tesi, M.D., Chief Executive Officer of INmune Bio. “For our existing pipeline, we are looking to the up-coming Phase II trials for INB03 and Phase 1 trials of INKmune™ in Cancer and XPro1595 for Alzheimer’s Disease. Also, we expanded our pipeline with the launch of our NeuLiv™ program for the treatment of NASH which we expect to start a Phase 2a trial next year. Looking ahead, the team at INmune Bio is focused on executing against our upcoming milestones to maximize shareholder value.” Upcoming Milestones: 4Q19 – First patient enrolled XPro1595 Alzheimer’s Disease trial1H20 – Initiate INB03 Phase II cancer trial2H20 – Initiate NeuLiv™ Phase IIa trial in NASH2H20 – First patient enrolled INKmune™ cancer trial2H20 – Phase I data on Alzheimer’s Disease XPro1595 AD data Financial Results for the Third Quarter Ended September 30, 2019: Net loss attributable to common stockholders for the third quarter ended September 30, 2019 was $3.1 million, compared to $1.5 million for the quarter ended September 30, 2018. Research and development...